Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...
A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...
Ever-Growing USA on MSN21h
Retratutide: Eli Lilly’s Groundbreaking Drug Poised to Transform Obesity and Diabetes TreatmentIn the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...
Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback